Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report)'s stock price fell 2.4% during trading on Wednesday . The stock traded as low as $13.31 and last traded at $13.54. 232,394 shares changed hands during trading, a decline of 73% from the average session volume of 850,806 shares. The stock had previously closed at $13.88.
Analyst Ratings Changes
NAGE has been the subject of several research analyst reports. Roth Capital restated a "buy" rating and issued a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Saturday, June 14th. Finally, Canaccord Genuity Group lifted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th.
Check Out Our Latest Analysis on Niagen Bioscience
Niagen Bioscience Stock Performance
The company has a market cap of $1.06 billion, a PE ratio of 149.33 and a beta of 2.08. The stock's 50-day simple moving average is $10.06 and its 200 day simple moving average is $7.38.
Niagen Bioscience Company Profile
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Further Reading
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
